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M.D., Seung Gyun In, M.D., Jeong Hyun Shin, M.D., Ph.D., Gwang Seong Choi, M.D., Ph.D.
Department of Dermatology, Inha University School of Medicine, Incheon, Korea
Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of 
the epidermal growth factor receptor (EGFR). Erlotinib has 
been used primarily to treat non-small cell lung cancer. In 
addition to its role in tumor cells, EGFR is also an important 
regulator of growth and differentiation in the skin and hair. 
Therefore, EGFR-TKIs have been associated with a number of 
cutaneous side effects including follicular acneiform erup-
tions, cutaneous xerosis, chronic paronychia, desquama-
tion, seborrheic dermatitis, and hair texture changes. He-
rein, we report a rare case of a 61-year-old woman who was 
treated with erlotinib and experienced cicatricial alopecia.
(Ann Dermatol 23(S3) S350∼S353, 2011)
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INTRODUCTION
Erlotinib is a tyrosine kinase inhibitor (TKI) that selectively 
inhibits the epidermal growth factor receptor (EGFR). It 
acts by inhibiting intracellular phosphorylation of the 
tyrosine kinase associated with the EGFR
1. EGFR-TKIs are 
currently used in the treatment of a number of solid 
tumors. Various cutaneous side effects of EGFR-TKIs have 
been reported, including acneiform eruptions, chronic pa-
ronychia, xerosis, a seborrheic dermatitis-like eruption, 
changes in hair texture, and nonscarring alopecia
1. The 
most common skin manifestation is a rash that has been 
described as a follicular or papulopustular eruption. How-
ever, significant or severe alopecia has rarely been repor-
ted in patients that receive EGFR-TKI monotherapy
1,2.
CASE REPORT
A 61-year-old woman with metastatic non-small cell lung 
cancer (NSCLC) presented with erythematous erosive 
patches containing pustules on her scalp. She had been 
using 150 mg/day erlotinib (Tarceva
Ⓡ) for 11 months. Two 
months after starting drug administration, she experienced 
a mild acneiform facial eruption. By applying a topical 
macrolide, it improved after several days. However, about 
9 months after taking the medicine, painful, erosive pat-
ches appeared on her scalp, which was accompanied by 
hair loss. Physical examination showed erythematous ero-
sive patches with follicular pustules on the scalp (Fig. 1). 
No other adverse events were observed, including xero-
derma or inflammation of the nails. A biopsy specimen 
taken from the scalp showed ruptured hair follicles and 
abundant perifollicular infiltrate with lymphocytes and 
neutrophils (Fig. 2). Bacterial and fungal stains were 
negative, but Staphylococcus  aureus was cultured from 
the pustules. Routine laboratory investigation found no 
significant abnormalities.
Treatment with topical and oral steroids plus antibiotics 
was started and continued for 5 weeks. The dosage of 
erlotinib was decreased from 150 mg/day to 100 mg/day, 
and then the erythematous, pustular skin lesion gradually 
improved. However, an atrophic alopecic patch devel-
oped on her scalp (Fig. 3). The final diagnosis was cica-
tricial alopecia, and the alopecic lesion remained un-
changed during a 9-months follow-up.
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Fig. 1. Erythematous erosive patches containing follicular pus-
tules on the scalp.
Fig. 2. (A) Skin biopsy from the scalp showing ruptured hair follicles (H&E, ×40). (B) Abundant perifollicular infiltrate with lymphocytes
and neutrophils (H&E, ×200).
Fig. 3. Erythematous scarring, alopecic patches on the scalp.
DISCUSSION
EGFR inhibitors have been approved for the treatment of 
NSCLC, pancreatic cancer, colorectal cancer and head 
and neck cancer
3. Targeting the EGFR pathway with a 
small-molecule EGFR-TKI (erlotinib) or a monoclonal 
antibody (cetuximab) prolonged survival in patients with 
advanced disease in both the first- and second-line 
settings
4.
EGFR inhibitors can cause a range of adverse cutaneous 
reactions of variable severity. The most common skin 
toxicity is an acneiform or papulopustular rash that pri-
marily affects the sebaceous areas of the scalp, face, and 
upper trunk. The rash can be itchy and, as a result, com-
plicated by a secondary bacterial infection. The second 
most common skin toxicity affects the nails and includes 
symptoms such as discoloration, pitting, and paronychia
3. 
Patients treated with EGFR inhibitors also sometimes 
exhibit hair abnormalities, like excessive eyelash and 
eyebrow growth or curly/wavy hair on the face or scalp 
that is both fine and brittle
2,3. Substantial alopecia is 
uncommon. A literature search identified five other cases 
of alopecia associated with EGFR inhibitors; but, only one 
case of cicatricial alopecia was reported (Table 1)
1,2,5-7.
The mechanism underlying the folliculocentric rash re-
mains unclear, although it is known that EGFR inhibitors 
can have several adverse effects on epithelial homeostasis. 
EGFR is strongly expressed in the basal layer of the 
epidermis, with lower expression in the lower dermal 
papilla, outer root sheath of the hair follicle, outer sheath BH Yang, et al
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Table 1. Published English-language reports of alopecia associated with the use of EGFR inhibitors
Reference Age Sex Diagnosis Treatment Characteristics
Pongpudpunth et al., 2009
1 60 Female   Stage I NSCLC  Erlotinib 150 mg/d   Trichomegaly and alopecia
Costa et al., 2007
2 74 Female   Stage IV NSCLC  Erotinib 150 mg/d   Alopecia
Donovan et al., 2008
5 70 Female   Stage IV NSCLC  Genitinib 250 mg/d   Scaring alopecia
Graves et al., 2006
6 65 Female   NSCLC  Genitinib   Inflammatory nonscaring allopecia
Robert et al., 2005
7 Unknown Female   Unknown  EGFR inhibitor   Frontal alopecia
EGFR: epidermal growth factor receptor, NSCLC: non-small cell lung cancer.
of the upper hair shaft, sebaceous glands, and eccrine 
sweat glands. Inhibiton of these EGFRs leads to growth 
and migratory abnormalities that result in a papulopustular 
rash and impaired differentiation
3,8 .
Several studies have shown that EGFRs play an essential 
role in the maintenance of normal hair follicles. In 2002, 
Kimyai-Asadi and Jih
9 reported that a chimeric anti-EGFR 
antibody was toxic to follicles. EGFR-knockout mice had 
thin skin with poorly defined stratification and altered 
terminal differentiation of the epidermis and hair follicles. 
Failure of hair to enter the catagen stage resulted in a 
severe inflammatory reaction in the surrounding skin, 
follicular necrosis, and alopecia. In addition to its essential 
role in hair cycle regulation, EGFR also plays a role in 
regulating inflammation. This could be important to the 
pathogenesis of inflammatory infiltration and the 
destruction of hair follicles
6. Based on these observations, 
the folliculocentric pustular rash was not considered to be 
the cause of infection; moreover, this hypothesis was 
supported by results obtained in microbiological cultures. 
The folliculocentric puspular rash is thought to result from 
abnormal keratinization, follicular retention and 
subsequent rupture of the affected hair follicle
10. The 
present case exhibited erosive patches and pustules on the 
scalp, and S. aureus was cultured form the pustules. 
Histological findings showed folliculitis with an infiltrate 
of mixed inflammatory cells. We postulated that these 
findings were likely due to a secondary infection that 
resulted from abnormal keratinization of the hair follicles 
and a failure to control the inflammatory process due to 
EGFR inhibition. 
During most of the hair cycle, the lower portion of the 
hair follicle is an immune-privileged site
6. However, 
during follicle regression in the catagen stage, major histo-
compatibility complex class 1 antigens are expressed in 
the lower portion of the follicle, then activated macro-
phages infiltrate the area and the lower portion of the 
follicle degenerates
6. EGFR induces suppression of free 
radical production, which might be necessary to control 
the inflammation process. Without this EGFR function, the 
expression of major histocompatibility complex class 1 
antigens in the early catagen stage and the following 
inflammatory response could lead to the destruction of the 
hair follicle
6. Thus, it is possible that cicatricial alopecia 
resulted from immune privilege failure in the hair follicle. 
Alternatively, development of cicatricial alopecia may 
result from various stimuli that induce the inflammatory 
infiltrate
11. Possible antigenic stimuli include ultraviolet 
light in patients with discoid lupus erythematous in the 
scalp, certain medications in patients with lichen plano-
pilaris, and S. aureus infection in patients with folliculitis 
decalvans
11. In the case presented here, S. aureus may 
have aggravated the course of EGFR- induced cicatricial 
alopecia development.
Cicatricial alopecia caused by an EGFR inhibitor is rela-
tively rare. Generally no bacteria are associated with folli-
cular inflammation induced by treatment with an EGFR 
inhibitor. However, S. aureus was identified in this case. 
Histological findings indicated that S. aureus might have 
continued to break up follicular units and thus, aggravated 
inflammation. We hypothesized that these conditions mi-
ght have caused cicatrical alopecia; however, accurate 
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